menu

Ovarian Cancer

As a biosimilar investigator, you can offer your patients immediate access to active biologic therapy at no cost… and ultimately contribute to more affordable treatment worldwide

Recent FDA and EMA approvals of the anti-angiogenic biologic bevacizumab for relapsed platinum-resistant ovarian cancer in 2014 gave new hope to patients with a bleak prognosis. The high cost of bevacizumab currently puts it beyond the reach of many eligible patients – but, as its patent expiry approaches, new manufacturers are able to begin developing less costly versions known as biosimilars. For regulatory approval, biosimilars need to demonstrate comparable safety and efficacy to the originator biologic in a head-to-head clinical trial.

Ovarian cancer – still the deadliest gynecological malignancy   +

Ovarian cancer, the fifth most commonly diagnosed female cancer,1 causes a disproportionate number of deaths as it is usually advanced by the time of diagnosis.1,2 With non-specific symptoms and no screening tests, ovarian cancer often spreads unnoticed before many women even know they have it. Less than 50% of patients survive for more than 5 years once diagnosed.2 In 2012, there were around a quarter of a million new cases and more than 150,000 deaths from ovarian cancer worldwide.2 For patients with relapsed, platinum-resistant disease, prospects are particularly bleak.
Recent advances are a cause for optimism...   +

Research into targeted treatments for specific genetic subtypes of ovarian cancer is gaining pace but probably the most significant recent development in the field was approval in 2014 from both the FDA and EMA for use of the anti-angiogenic biologic bevacizumab (anti-VEGF monoclonal antibody) in relapsed platinum-resistant ovarian cancer, the most refractory subgroup.3 Based on the results of an international Phase III study – which showed a 62% improvement in progression-free survival with bevacizumab plus chemotherapy versus chemotherapy alone4  – this development represented the first significant therapeutic advance for these hard-to-treat patients since the turn of the century.3 Bevacizumab is also approved in the EU for both treatment-naïve and relapsed, platinum-sensitive ovarian cancer.

Biosimilar Knowledge Connect Ovarian Cancer Single Quote

...but many patients can’t benefit because of the cost   +

Unfortunately many patients with cancer are not able to reap the benefits of modern research. The reason, of course, is cost. Around the world, healthcare authorities and insurers are declining to fund cutting-edge cancer therapies because of their high price tags – and patients who decide to self-fund are frequently faced with a significant financial burden.6,7,8 In some developing countries, cancer biologics may be out of reach for virtually the entire population. Even in the Western world, large discrepancies in patient access to biologics exist.9,10

The UK’s National Institute for Health and Care Excellence (NICE) has repeatedly declined to fund bevacizumab on the National Health Service (NHS) for eligible patients with ovarian cancer as well as for other licensed indications such as colorectal cancer and non-small cell lung cancer.11 Similarly, in the USA, bevacizumab is prescribed by oncologists for many cancer types but its cost remains a barrier to patient access.12 A recent survey of US managed care organizations (MCOs) indicated that two-thirds would lower co-insurance charges for bevacizumab if it were less expensive.13

Biosimilar Knowledge Connect Ovarian Cancer Group Quotes

Patent expiry permits introduction of less costly biologics known as biosimilars   +

The prices of novel cancer biologics reflect the scientific innovation and the investment required to support biotechnological research and development. But it puts them beyond the reach of many people. Pursuit of innovative new drugs is clearly of great importance, but so is broadening patient access to the treatments we have now.

There’s no quick-fix solution – but, as biologic drugs like bevacizumab start to approach patent expiry, the opportunity arises for new manufacturers to develop less costly versions of them, which are most commonly known as biosimilars.*

*also known as follow-on biologics, subsequent-entry biologics and biocomparables, among others

What are biosimilars?   +

Unlike the generics of the chemical drug world, biosimilars are not exact copies of originator biologics, as it is not possible for a new manufacturer to precisely replicate the highly complex and sophisticated production processes. However, extensive regulatory requirements are designed to ensure that candidate biosimilars must be rigorously compared with their originators both analytically and clinically, to establish that quality, efficacy, and safety are all a very close match. By January 2016, 22 biosimilars in a range of therapy areas had been launched in Europe with no adverse clinical consequences compared with their originators17,18 – and have resulted in significant cost savings.19

The extent of the testing required means that biosimilars can’t be as heavily discounted as chemical generics. The average saving is projected to be 20–30%,20 but it could well be higher. For a biologic that can cost up to USD $100,0007,21,22 for a year of treatment, these savings are highly worthwhile. In addition, the introduction of competition can prompt the manufacturers of originator biologics to reduce their prices, and to consider investing in innovative new products as they seek new competitive advantages.

Learn more about BiosimilarsRegulatory Requirements, and Biosimilars by Region.

Become a bevacizumab biosimilar investigator   +

Bevacizumab is targeted for biosimilar development in a number of indications. Importantly, its efficacy does not depend on the presence of specific genetic mutations and its tolerability is well defined and generally manageable.23,24

Quintiles is actively supporting the development of biosimilar versions of bevacizumab in ovarian cancer and we invite you to join us as a clinical investigator. The patients you enroll in these studies will all receive active therapy, either with the branded biologic or a biosimilar candidate at no cost to them or to their insurers. Even if you perceive that patient access to biologics like bevacizumab is not a critical issue in your own country, getting involved in biosimilar clinical trials will give you the opportunity to help maintain the high standards of biosimilar studies, gain experience in an area of research projected to expand significantly, and be part of a global mission to bring the benefits of modern cancer treatment to a far wider population.

Learn more about working with Quintiles.

Why partner with Quintiles?   +

  • We’ve worked with tens of thousands of clinical research sites worldwide since 1982
  • We helped to develop or commercialize all of the top 50 best-selling biotechnology products or compounds of 2013 
  • We’ve supported the development of biosimilars for more than 10 different originator biologics including monoclonal antibodies 
  • We established Biosimilars Knowledge Connect in 2012 to educate and engage investigators in biosimilar research
References   +

1. Colombo N, Peiretti M, Parma G et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 21 (Suppl 5):v23–v30. 
2. World Cancer Research Fund, American Institute for Cancer Research. Ovarian Cancer 2014 Report. http://www.aicr.org/continuous-update-project/reports/ovarian-cancer-2014-report.pdf. Accessed 11 February 2015.
3. OncLive, 14 November 2014. FDA approves bevacizumab for recurrent ovarian cancer. http://www.onclive.com/web-exclusives/FDA-Approves-Bevacizumab-for-Recurrent-Ovarian-Cancer. Accessed 9 February  2015.
4. Pujade-Lauraine E, Hilpert F, Weber B et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized Phase III trial. JCO (2014) 32:1302–1308.
5. Bevacizumab extends PFS in platinum-resistant ovarian cancer. Oncology Times UK (2012) 9:6. http://journals.lww.com/oncotimesuk/Fulltext/2012/07000/Bevacizumab_extends_PFS_in_platinum_resistant.1.aspx. Accessed 9 February 2015. 
6. Express, 16 March 2014. The good fight: A drug that can add years to lives of ovarian cancer patients. http://www.express.co.uk/life-style/health/464835/Ovarian-cancer-drug-Avastin-can-add-years-to-lives-of-patients. Accessed 11 February 2015.
7. KevinMD.com, 24 April 2014. Treating cancer should not be paved in our patients’ financial despair. http://www.kevinmd.com/blog/2014/04/treating-cancer-paved-patients-financial-despair.html. Accessed 11 February 2015.
8. RiehlWorldView, 6 August 2010. ObamaCare: Why Avastin matters. http://riehlworldview.com/2010/08/obamacare-why-avastin-matters.html. Accessed 11 February 2015.
9. National Institute for Health and Care Excellence (NICE), 22 May 2013. NICE finds advanced ovarian cancer treatment too expensive with not enough benefit. https://www.nice.org.uk/news/press-and-media/nice-finds-advanced-ovarian-cancer-treatment-too-expensive-with-not-enough-benefit. Accessed 11 February 2015.
10. News.com.au, 8 August 2014. Avastin, first new ovarian cancer treatment in 15 years, subsidised.  http://www.news.com.au/lifestyle/health/avastin-first-new-ovarian-cancer-treatment-in-15-years-subsidised/story-fneuzlbd-1227017130109. Accessed 11 February 2015.
11. PMLiVE, 26 March 2013. Another NICE rejection for Roche’s Avastin. http://www.pmlive.com/pharma_news/another_nice_rejection_for_roches_avastin_469208. Accessed 9 February 2015.
12. NEWS Medical. Avastin (bevacizumab) price. http://www.news-medical.net/health/Avastin-(Bevacizumab)-Price.aspx. Accessed 9 February  2015. 
13. Decision Resources, 28 September 2009. Although most surveyed oncologists prescribe it for many cancer types, Avastin’s high cost remains a barrier to treatment for some patients.https://decisionresourcesgroup.com/press-releases/123996-although-most-surveyed-oncologists-prescribe-it-for-many-cancer-types-avastins-high-cost-remains-a-barrier-to-treatment-for-some-patients/. Accessed 10 October 2016.
14. Express, 16 March 2014. The good fight: A drug that can add years to lives of ovarian cancer patients. http://www.express.co.uk/life-style/health/464835/Ovarian-cancer-drug-Avastin-can-add-years-to-lives-of-patients. Accessed 11 February 2015.
15. World Health Organization 2014. International Agency for Research on Cancer. Press Release no. 224: Global battle against cancer won’t be won with treatment alone. Effective prevention measures urgently needed to prevent cancer crisis. http://www.iarc.fr/en/media-centre/pr/2014/pdfs/pr224_E.pdf.  Accessed 12 November 2014. 
16. Velpandian T, Sharma C, Garg SP et al. Safety and cost-effectiveness of single dose dispensing of bevacizumab for various retinal pathologies in developing countries. Indian J Ophthalmol (2007) 55:488–490. 
17. Ebbers HC, Crow SA, Vulto AG & Schellekens H. Interchangeability, immunogenicity and biosimilars. Nature Biotechnol (2012) 30:1186–1190.
18. McCamish M & Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther (2012) 91:405–417.
19. Rovira J, Espín J, García L & Olry de Labry A, 2011. The impact of biosimilars’ entry in the EU market. Andalusian School of Public Health.
20. PharmTech.com, 30 September 2014. New report details players and pipelines in the biosimilar space. http://www.pharmtech.com/pharmtech/News/New-Report-Details-Players-and-Pipelines-in-the-Bi/ArticleStandard/Article/detail/855810. Accessed 12 November 2014.
21. FiercePharma, 27 June 2014. EU backs Roche's Avastin for hard-to-treat ovarian cancer. http://www.fiercepharma.com/story/eu-backs-roches-avastin-hard-treat-ovarian-cancer/2014-06-27. Accessed 11 February 2015.
22. ScienceDaily, 1 June 2014. Ovarian cancer subtypes may predict response to bevacizumab. http://www.sciencedaily.com/releases/2014/06/140601201956.htm. Accessed 11 February 2015.
23. González Martín A, Redondo A, Jurado M et al. GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clin Transl Oncol (2013)15: 509–525.
24. The ASCO Post, 1 May 2014. AURELIA Trial: Adding bevacizumab to chemotherapy improves outcomes in platinum-resistant recurrent ovarian cancer. http://www.ascopost.com/issues/may-1,-2014/aurelia-trial-adding-bevacizumab-to-chemotherapy-improves-outcomes-in-platinum-resistant-recurrent-ovarian-cancer.aspx. Accessed 11 February 2015.
Video Spotlights
Considering a biosimilars trial?
Considering a biosimilars trial?
Investigator perspective: Oncology: Improving access to biologics
Investigator perspective: Oncology: Improving access to biologics